Phase 3 Readout

NTLA: Phase 3 Topline: HAELO: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the

Name: Phase 3 Topline: HAELO: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the
Start: 2027-09-01
End: 2027-09-01

September 1, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: September 1, 2027
Company: Intellia Therapeutics, Inc. (NTLA)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: HAELO: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the

September 1, 2027

NTLA overview →

Company: Intellia Therapeutics, Inc. (NTLA)
Indication: Hereditary Angioedema